WO1995006119A1
(en)
*
|
1993-08-24 |
1995-03-02 |
Scotgen Limited |
Recombinant humanized anti-human immunodeficiency virus antibody
|
US5472693A
(en)
*
|
1993-02-16 |
1995-12-05 |
The Dow Chemical Company |
Family of anti-carcinoembryonic antigen chimeric antibodies
|
US5856135A
(en)
*
|
1993-05-31 |
1999-01-05 |
Chugai Seiyaku Kabushiki Kaisha |
Reshaped human antibody to human interleukin-6
|
US5914110A
(en)
*
|
1993-09-07 |
1999-06-22 |
Smithkline Beecham Corporation |
Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
|
WO1995014041A1
(fr)
|
1993-11-19 |
1995-05-26 |
Chugai Seiyaku Kabushiki Kaisha |
Anticorps humain reconstitue contre des cellules medulloblastomateuses humaines
|
WO1995029690A1
(en)
*
|
1994-04-29 |
1995-11-09 |
The Trustees Of The University Of Pennsylvania |
Biologically active peptides and methods of identifying the same
|
US8017121B2
(en)
|
1994-06-30 |
2011-09-13 |
Chugai Seiyaku Kabushika Kaisha |
Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
|
CZ296919B6
(cs)
|
1994-10-07 |
2006-07-12 |
Chugai Seiyaku Kabushiki Kaisha |
Farmaceutický prípravek pro lécení chronické revmatické artritidy
|
CZ298325B6
(cs)
*
|
1994-10-21 |
2007-08-29 |
Kishimoto@Tadamitsu |
Farmaceutický prípravek pro prevenci nebo lécení plasmocytosy
|
WO1996025174A1
(fr)
*
|
1995-02-13 |
1996-08-22 |
Chugai Seiyaku Kabushiki Kaisha |
Inhibiteur de decomposition des proteines musculaires contenant un anticorps du recepteur de l'interleukine-6
|
DK0923941T3
(da)
*
|
1996-06-27 |
2006-09-18 |
Chugai Pharmaceutical Co Ltd |
Midler mod myelom der skal anvendes sammen med nitrogensennepantitumormidler
|
HUP9904177A3
(en)
|
1996-09-26 |
2001-10-29 |
Chugai Pharmaceutical Co Ltd |
Antibody against human parathormone related peptides
|
UA76934C2
(en)
*
|
1996-10-04 |
2006-10-16 |
Chugai Pharmaceutical Co Ltd |
Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
|
KR100655979B1
(ko)
|
1997-02-12 |
2006-12-08 |
츄가이 세이야꾸 가부시키가이샤 |
임파구계 종양의 치료제
|
ES2382488T3
(es)
|
1997-03-21 |
2012-06-08 |
Chugai Seiyaku Kabushiki Kaisha |
Un agente preventivo o terapéutico para enfermedades mediadas por células t sensibilizadas que comprende un antagonista de il-6 como ingrediente activo
|
EP1004313B1
(de)
|
1997-05-15 |
2007-05-02 |
Chugai Seiyaku Kabushiki Kaisha |
Heilmittel für kachexie
|
US20020187150A1
(en)
*
|
1997-08-15 |
2002-12-12 |
Chugai Seiyaku Kabushiki Kaisha |
Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
|
DK1004315T3
(da)
|
1997-08-15 |
2008-07-21 |
Chugai Pharmaceutical Co Ltd |
Forebyggende midler og/eller lægemidler indeholdende anti-IL6-receptorneutraliserende antistoffer til reduktion af urinproteinudskillelsen ved systemisk lupus erythematosus
|
JP4124573B2
(ja)
|
1998-03-17 |
2008-07-23 |
中外製薬株式会社 |
Il−6アンタゴニストを有効成分として含有する炎症性腸疾患の予防又は治療剤
|
SK14812000A3
(sk)
|
1998-04-03 |
2001-08-06 |
Chugai Seiyaku Kabushiki Kaisha |
Chimérny reťazec protilátky, chimérna protilátka, v oblasť, humanizovaný reťazec protilátky, humanizovaná protilátka, dna, expresný vektor, hostiteľ, spôsob prípravy a liečivo
|
DK1108435T3
(da)
*
|
1998-08-24 |
2007-02-05 |
Chugai Pharmaceutical Co Ltd |
Forebyggende midler eller midler mod pancreatitis indeholdende anti-IL-6-receptor-antistoffer som den aktive bestanddel
|
CA2352532C
(en)
|
1998-11-27 |
2014-10-14 |
Darwin Discovery Ltd. |
Compositions and methods for increasing bone mineralization
|
US7696325B2
(en)
|
1999-03-10 |
2010-04-13 |
Chugai Seiyaku Kabushiki Kaisha |
Polypeptide inducing apoptosis
|
AU7078200A
(en)
*
|
1999-08-27 |
2001-03-26 |
United States Of America, Represented By The Secretary, Department Of Health And Human Services, The |
Polypeptides, comprising il-6 ligand-binding receptor domains and related nucleic acids, antibodies, compositions, and methods of use
|
CA2388408A1
(en)
|
1999-10-01 |
2001-04-12 |
Chugai Seiyaku Kabushiki Kaisha |
Prevention and treatment of diseases associated with blood coagulation
|
GB0002666D0
(en)
|
2000-02-04 |
2000-03-29 |
Univ London |
Blockade of voltage dependent sodium channels
|
WO2001082968A1
(fr)
|
2000-04-28 |
2001-11-08 |
Chugai Seiyaku Kabushiki Kaisha |
Inhibiteurs de proliferation cellulaire
|
WO2002013860A1
(fr)
|
2000-08-11 |
2002-02-21 |
Chugai Seiyaku Kabushiki Kaisha |
Preparations stabilisees contenant un anticorps
|
WO2002032374A2
(en)
*
|
2000-10-18 |
2002-04-25 |
Immunex Corporation |
Methods for treating il-18 mediated disorders
|
WO2002033073A1
(fr)
|
2000-10-20 |
2002-04-25 |
Chugai Seiyaku Kabushiki Kaisha |
Anticorps agoniste degrade
|
CN1308447C
(zh)
|
2000-10-20 |
2007-04-04 |
中外制药株式会社 |
低分子化的激动剂抗体
|
JPWO2002033072A1
(ja)
|
2000-10-20 |
2004-02-26 |
中外製薬株式会社 |
低分子化tpoアゴニスト抗体
|
ES2298273T3
(es)
|
2000-10-25 |
2008-05-16 |
Chugai Seiyaku Kabushiki Kaisha |
Agentes preventivos o terapeuticos contra la psoriasis que contienen un antagonista de il-6 como su ingrediente activo.
|
WO2002036164A1
(fr)
*
|
2000-10-27 |
2002-05-10 |
Chugai Seiyaku Kabushiki Kaisha |
Agent abaissant le taux sanguin de vegf contenant un antagoniste de il-6 en tant que principe actif
|
AU2000279625A1
(en)
*
|
2000-10-27 |
2002-05-15 |
Chugai Seiyaku Kabushiki Kaisha |
Blood mmp-3 level-lowering agent containing il-6 antgonist as the active ingredient
|
US7931897B2
(en)
|
2001-02-07 |
2011-04-26 |
Chugai Seiyaku Kabushiki Kaisha |
Therapeutic agent for hematopoietic tumors
|
WO2002098370A2
(en)
*
|
2001-03-02 |
2002-12-12 |
Medimmune, Inc. |
Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
|
EP1380589A4
(de)
|
2001-03-09 |
2004-09-01 |
Chugai Pharmaceutical Co Ltd |
Verfahren zur proteinreinigung
|
UA80091C2
(en)
|
2001-04-02 |
2007-08-27 |
Chugai Pharmaceutical Co Ltd |
Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
|
EP1382964A4
(de)
|
2001-04-17 |
2009-06-10 |
Chugai Pharmaceutical Co Ltd |
Verfahren zur tensid-quantifizierung
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
ES2334494T5
(es)
*
|
2001-05-11 |
2013-05-29 |
Ludwig Institute For Cancer Research Ltd. |
Proteínas de unión específicas y usos de las mismas
|
AU2003211990A1
(en)
|
2002-02-14 |
2003-09-04 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody-containing solution pharmaceuticals
|
GB0208041D0
(en)
*
|
2002-04-08 |
2002-05-22 |
Lonza Biologics Plc |
Method of culturing animal cells
|
JPWO2003090779A1
(ja)
*
|
2002-04-25 |
2005-08-25 |
中外製薬株式会社 |
肺癌治療薬
|
JP4753578B2
(ja)
|
2002-06-03 |
2011-08-24 |
ジェネンテック, インコーポレイテッド |
合成抗体ファージライブラリー
|
AU2003257536A1
(en)
|
2002-08-27 |
2004-03-19 |
Chugai Seiyaku Kabushiki Kaisha |
Method of stabilizing protein solution preparation
|
AU2002338020A1
(en)
|
2002-09-04 |
2004-03-29 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody against blood-solubilized n-terminal peptide in gpc3
|
ES2558303T3
(es)
|
2002-09-11 |
2016-02-03 |
Chugai Seiyaku Kabushiki Kaisha |
Método de purificación de proteínas
|
AU2004212843B2
(en)
*
|
2003-02-24 |
2009-06-25 |
Chugai Seiyaku Kabushiki Kaisha |
Remedy for spinal injury containing interleukin-6 antagonist
|
JP2004279086A
(ja)
|
2003-03-13 |
2004-10-07 |
Konica Minolta Holdings Inc |
放射線画像変換パネル及び放射線画像変換パネルの製造方法
|
GB2401040A
(en)
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
CA2529623A1
(en)
|
2003-06-16 |
2005-02-17 |
Celltech R & D, Inc. |
Antibodies specific for sclerostin and methods for increasing bone mineralization
|
EP2204190A1
(de)
|
2003-07-15 |
2010-07-07 |
Chugai Seiyaku Kabushiki Kaisha |
IgM-Produktion durch umgewandelte Zellen und Verfahren zur Quantifizierung der IgM-Produktion
|
CA2542691C
(en)
|
2003-10-17 |
2013-09-24 |
Chugai Seiyaku Kabushiki Kaisha |
Il-6 antagonist for use as mesothelioma therapeutic agent
|
US8298816B2
(en)
*
|
2003-12-03 |
2012-10-30 |
Chugai Seiyaku Kabushiki Kaisha |
Expression systems using mammalian beta-actin promoter
|
US8617550B2
(en)
|
2003-12-19 |
2013-12-31 |
Chugai Seiyaku Kabushiki Kaisha |
Treatment of vasculitis with IL-6 antagonist
|
AR048210A1
(es)
*
|
2003-12-19 |
2006-04-12 |
Chugai Pharmaceutical Co Ltd |
Un agente preventivo para la vasculitis.
|
WO2005080429A2
(en)
*
|
2004-02-11 |
2005-09-01 |
Warner-Lambert Company Llc |
Methods of treating osteoarthritis with anti-il-6 or anti-il6 receptor antibodies
|
WO2005079479A2
(en)
*
|
2004-02-17 |
2005-09-01 |
Absalus, Inc. |
Super-humanized antibodies against respiratory syncytial virus
|
US7767792B2
(en)
*
|
2004-02-20 |
2010-08-03 |
Ludwig Institute For Cancer Research Ltd. |
Antibodies to EGF receptor epitope peptides
|
JPWO2005090405A1
(ja)
*
|
2004-03-24 |
2008-04-17 |
中外製薬株式会社 |
インターロイキン−6受容体に対するヒト型化抗体のサブタイプ
|
AR048335A1
(es)
|
2004-03-24 |
2006-04-19 |
Chugai Pharmaceutical Co Ltd |
Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
|
US7785903B2
(en)
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
GB0410627D0
(en)
*
|
2004-05-12 |
2004-06-16 |
Scancell Ltd |
Specific binding members
|
EP1810980A1
(de)
*
|
2004-10-28 |
2007-07-25 |
Osaka University |
Interleukin-6 inhibitoren
|
CA2593521C
(en)
|
2005-01-05 |
2016-06-21 |
Chugai Seiyaku Kabushiki Kaisha |
Cell culture method and utilization of the same
|
SI1859793T1
(sl)
*
|
2005-02-28 |
2011-08-31 |
Eisai R&D Man Co Ltd |
Nova kombinirana uporaba sulfonamidne spojine za zdravljenje raka
|
WO2006106903A1
(ja)
|
2005-03-31 |
2006-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
sc(Fv)2構造異性体
|
EP1870459B1
(de)
|
2005-03-31 |
2016-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
Verfahren zur polypeptidherstellung mit regulation des zusammenbaus
|
PA8672101A1
(es)
|
2005-04-29 |
2006-12-07 |
Centocor Inc |
Anticuerpos anti-il-6, composiciones, métodos y usos
|
US8003108B2
(en)
|
2005-05-03 |
2011-08-23 |
Amgen Inc. |
Sclerostin epitopes
|
US7592429B2
(en)
|
2005-05-03 |
2009-09-22 |
Ucb Sa |
Sclerostin-binding antibody
|
PT1888123E
(pt)
|
2005-06-08 |
2013-03-13 |
Janssen Biotech Inc |
Uma terapêutica celular para a degeneração ocular
|
CN101237890A
(zh)
|
2005-06-10 |
2008-08-06 |
中外制药株式会社 |
含有葡甲胺的蛋白质制剂的稳定剂及其利用
|
CN101262885B
(zh)
|
2005-06-10 |
2015-04-01 |
中外制药株式会社 |
含有sc(Fv)2的药物组合物
|
NZ595386A
(en)
*
|
2005-08-11 |
2013-08-30 |
Arpi Matossian Rogers |
Peptides for treatment and diagnosis of autoimmune disease
|
CN101330929B
(zh)
*
|
2005-10-14 |
2014-03-05 |
学校法人福冈大学 |
胰岛移植中的移植胰岛障碍抑制剂
|
EP1941908B1
(de)
|
2005-10-21 |
2015-08-19 |
Chugai Seiyaku Kabushiki Kaisha |
Therapeutisches mittel gegen herzerkrankungen
|
US8679490B2
(en)
|
2005-11-07 |
2014-03-25 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
|
JP5398987B2
(ja)
|
2005-11-14 |
2014-01-29 |
セルミド リミテッド |
調節性t細胞の機能異常に基づく疾患の治療方法及び予防方法
|
AR057582A1
(es)
|
2005-11-15 |
2007-12-05 |
Nat Hospital Organization |
Agentes para suprimir la induccion de linfocitos t citotoxicos
|
AR057941A1
(es)
|
2005-11-25 |
2007-12-26 |
Univ Keio |
Agentes terapeuticos para el cancer de prostata
|
JP5231810B2
(ja)
|
2005-12-28 |
2013-07-10 |
中外製薬株式会社 |
抗体含有安定化製剤
|
EP3135298B1
(de)
|
2006-01-27 |
2018-06-06 |
Keio University |
Therapeutische mittel für erkrankungen im zusammenhang mit choroidaler neovaskularisation
|
JP5553506B2
(ja)
|
2006-03-22 |
2014-07-16 |
中外製薬株式会社 |
エリスロポエチン溶液製剤
|
ES2568436T3
(es)
|
2006-03-31 |
2016-04-29 |
Chugai Seiyaku Kabushiki Kaisha |
Procedimiento para controlar la farmacocinética en sangre de anticuerpos
|
EP2009101B1
(de)
*
|
2006-03-31 |
2017-10-25 |
Chugai Seiyaku Kabushiki Kaisha |
Antikörpermodifikationsverfahren für die aufreinigung eines bispezifischen antikörpers
|
WO2007116962A1
(ja)
|
2006-04-07 |
2007-10-18 |
Osaka University |
筋再生促進剤
|
US8741643B2
(en)
|
2006-04-28 |
2014-06-03 |
Lifescan, Inc. |
Differentiation of pluripotent stem cells to definitive endoderm lineage
|
SG172625A1
(en)
*
|
2006-05-25 |
2011-07-28 |
Glaxo Group Ltd |
Modified humanised anti-interleukin-18 antibodies
|
PT2374818E
(pt)
|
2006-06-02 |
2013-02-13 |
Regeneron Pharma |
Anticorpos com elevada afinidade para o receptor il-6 humano
|
US8080248B2
(en)
|
2006-06-02 |
2011-12-20 |
Regeneron Pharmaceuticals, Inc. |
Method of treating rheumatoid arthritis with an IL-6R antibody
|
PL2032166T3
(pl)
*
|
2006-06-13 |
2013-09-30 |
Oncomed Pharm Inc |
Kompozycje i sposoby diagnozowania i leczenia nowotworów
|
ES2405618T3
(es)
|
2006-06-21 |
2013-05-31 |
Oncotherapy Science, Inc. |
Anticuerpos monoclonales dirigidos a tumores para FZD10 y usos de los mismos
|
US8629244B2
(en)
|
2006-08-18 |
2014-01-14 |
Ablynx N.V. |
Interleukin-6 receptor binding polypeptides
|
US20080081041A1
(en)
*
|
2006-09-29 |
2008-04-03 |
Jeffrey Nemeth |
Method of Using IL6 Antagonists with Mitoxantrone for Prostate Cancer
|
CL2008000188A1
(es)
*
|
2007-01-23 |
2008-07-18 |
Chugai Pharmaceutical Co Ltd |
Agente para suprimir la reaccion de rechazo cronica que comprende como ingrediente activo un inhibidor de il-6; y uso del inhibidor de il-6.
|
JP5618544B2
(ja)
|
2007-01-24 |
2014-11-05 |
オンコメッドファーマシューティカルズ インコーポレイテッド |
癌の診断および処置のための組成物および方法
|
WO2008091701A2
(en)
|
2007-01-25 |
2008-07-31 |
Dana-Farber Cancer Institute |
Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
|
CL2008000719A1
(es)
|
2007-03-12 |
2008-09-05 |
Univ Tokushima Chugai Seiyaku |
Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
|
US8252286B2
(en)
*
|
2007-05-21 |
2012-08-28 |
Alderbio Holdings Llc |
Antagonists of IL-6 to prevent or treat thrombosis
|
US20090238825A1
(en)
*
|
2007-05-21 |
2009-09-24 |
Kovacevich Brian R |
Novel rabbit antibody humanization methods and humanized rabbit antibodies
|
US8178101B2
(en)
|
2007-05-21 |
2012-05-15 |
Alderbio Holdings Inc. |
Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
|
US9701747B2
(en)
|
2007-05-21 |
2017-07-11 |
Alderbio Holdings Llc |
Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
|
KR101615715B1
(ko)
*
|
2007-05-21 |
2016-04-27 |
앨더바이오 홀딩스 엘엘씨 |
Il-6에 대한 항체 및 이의 용도
|
US8404235B2
(en)
*
|
2007-05-21 |
2013-03-26 |
Alderbio Holdings Llc |
Antagonists of IL-6 to raise albumin and/or lower CRP
|
EP2162469A4
(de)
*
|
2007-05-21 |
2012-08-01 |
Alderbio Holdings Llc |
Neue verfahren zur humanisierung von kaninchenantikörpern und humanisierte kaninchenantikörper
|
US8062864B2
(en)
|
2007-05-21 |
2011-11-22 |
Alderbio Holdings Llc |
Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
|
US7906117B2
(en)
*
|
2007-05-21 |
2011-03-15 |
Alderbio Holdings Llc |
Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
|
JP5142265B2
(ja)
|
2007-05-28 |
2013-02-13 |
独立行政法人産業技術総合研究所 |
抗モータリン抗体のパラトープ及びエピトープ
|
US9080145B2
(en)
|
2007-07-01 |
2015-07-14 |
Lifescan Corporation |
Single pluripotent stem cell culture
|
US20100129355A1
(en)
*
|
2007-07-26 |
2010-05-27 |
Osaka University |
Therapeutic agents for ocular inflammatory disease comprising interleukin 6 receptor inhibitor as active ingredient
|
WO2009018453A1
(en)
|
2007-07-31 |
2009-02-05 |
Lifescan, Inc. |
Differentiation of human embryonic stem cells
|
US9283276B2
(en)
|
2007-08-14 |
2016-03-15 |
Ludwig Institute For Cancer Research Ltd. |
Monoclonal antibody 175 targeting the EGF receptor and derivatives and uses thereof
|
CL2008002775A1
(es)
|
2007-09-17 |
2008-11-07 |
Amgen Inc |
Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
|
MY180713A
(en)
*
|
2007-09-26 |
2020-12-07 |
Chugai Pharmaceutical Co Ltd |
Modified antibody constant region
|
CN106519025B
(zh)
*
|
2007-09-26 |
2021-04-23 |
中外制药株式会社 |
利用cdr的氨基酸取代来改变抗体等电点的方法
|
CA2700498C
(en)
|
2007-09-26 |
2016-01-05 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-il-6 receptor antibody
|
EP2196220B1
(de)
|
2007-10-02 |
2014-12-03 |
Chugai Seiyaku Kabushiki Kaisha |
Inhibierende anti-IL-6 Rezeptor Antikörper für die Behandlung von Graft-versus-Host-Reaktion
|
CN103540632A
(zh)
|
2007-10-15 |
2014-01-29 |
中外制药株式会社 |
抗体的制备方法
|
CA2706560C
(en)
|
2007-11-27 |
2017-02-28 |
Lifescan, Inc. |
Differentiation of human embryonic stem cells to pancreatic cells
|
AU2008332271C1
(en)
|
2007-12-05 |
2014-04-24 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-NR10 antibody and use thereof
|
WO2009075344A1
(ja)
|
2007-12-12 |
2009-06-18 |
Japan As Represented By Director General Of Agency Of National Cancer Center |
M-csf受容体を分子標的とするmll白血病及びmoz白血病治療剤、およびその利用
|
PE20091174A1
(es)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
WO2009095489A2
(en)
*
|
2008-02-01 |
2009-08-06 |
Ablynx N.V. |
Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
|
JP5733986B2
(ja)
|
2008-02-21 |
2015-06-10 |
ヤンセン バイオテツク,インコーポレーテツド |
細胞の付着、培養、及び剥離のための方法、表面改質されたプレート、並びに組成物
|
PL2708558T3
(pl)
|
2008-04-11 |
2018-09-28 |
Chugai Seiyaku Kabushiki Kaisha |
Cząsteczka wiążąca antygen zdolna do wiązania dwóch lub więcej cząsteczek antygenu w sposób powtarzalny
|
US8623648B2
(en)
|
2008-04-24 |
2014-01-07 |
Janssen Biotech, Inc. |
Treatment of pluripotent cells
|
EP2282769A4
(de)
*
|
2008-04-29 |
2012-04-25 |
Abbott Lab |
Dual-variable- domain-immunglobuline und ihre verwendungen
|
MX2010012031A
(es)
|
2008-05-13 |
2011-01-20 |
Novimmune Sa |
Anticuerpos anti-il-6/il-6r y metodos de uso de los mismos.
|
PE20100092A1
(es)
|
2008-06-03 |
2010-03-12 |
Abbott Lab |
Inmunoglobulina con dominio variable dual y usos de la misma
|
KR20110016959A
(ko)
|
2008-06-03 |
2011-02-18 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
CA2728243C
(en)
|
2008-06-05 |
2020-03-10 |
National Cancer Center |
Il-6 inhibitor for suppressing neuroinvasion in pancreatic cancer
|
US8188235B2
(en)
|
2008-06-18 |
2012-05-29 |
Pfizer Inc. |
Antibodies to IL-6 and their uses
|
PL2942392T3
(pl)
|
2008-06-30 |
2019-02-28 |
Janssen Biotech, Inc |
Różnicowanie pluripotencjalnych komórek macierzystych
|
RS53924B1
(en)
|
2008-07-08 |
2015-08-31 |
Oncomed Pharmaceuticals, Inc. |
NOTCH-BINDING AGENTS AND ANTAGONISTS AND PROCEDURES FOR THEIR USE
|
US9132189B2
(en)
|
2008-07-08 |
2015-09-15 |
Oncomed Pharmaceuticals, Inc. |
Notch1 binding agents and methods of use thereof
|
MX2010014574A
(es)
|
2008-07-08 |
2011-04-27 |
Abbott Lab |
Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
|
TWI440469B
(zh)
*
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
MX349178B
(es)
|
2008-10-31 |
2017-07-17 |
Centocor Ortho Biotech Inc |
Diferenciación de células madre embrionarias humanas al linaje endocrino pancreático.
|
WO2010051223A1
(en)
|
2008-10-31 |
2010-05-06 |
Centocor Ortho Biotech Inc. |
Differentiation of human embryonic stem cells to the pancreatic endocrine lineage
|
KR101687344B1
(ko)
|
2008-11-20 |
2016-12-16 |
얀센 바이오테크 인코포레이티드 |
평면 기재상의 세포 부착 및 배양을 위한 방법 및 조성물
|
EP2366021B1
(de)
|
2008-11-20 |
2017-08-02 |
Janssen Biotech, Inc. |
Pluripotente stammzellkultur auf mikroträgern
|
US8992920B2
(en)
|
2008-11-25 |
2015-03-31 |
Alderbio Holdings Llc |
Anti-IL-6 antibodies for the treatment of arthritis
|
US8337847B2
(en)
|
2008-11-25 |
2012-12-25 |
Alderbio Holdings Llc |
Methods of treating anemia using anti-IL-6 antibodies
|
US8420089B2
(en)
|
2008-11-25 |
2013-04-16 |
Alderbio Holdings Llc |
Antagonists of IL-6 to raise albumin and/or lower CRP
|
US9212223B2
(en)
|
2008-11-25 |
2015-12-15 |
Alderbio Holdings Llc |
Antagonists of IL-6 to prevent or treat thrombosis
|
US9452227B2
(en)
|
2008-11-25 |
2016-09-27 |
Alderbio Holdings Llc |
Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
|
US8323649B2
(en)
|
2008-11-25 |
2012-12-04 |
Alderbio Holdings Llc |
Antibodies to IL-6 and use thereof
|
JP5717624B2
(ja)
|
2009-03-19 |
2015-05-13 |
中外製薬株式会社 |
抗体定常領域改変体
|
TWI682995B
(zh)
|
2009-03-19 |
2020-01-21 |
日商中外製藥股份有限公司 |
抗體恆定區域改變體
|
RU2539798C2
(ru)
|
2009-04-10 |
2015-01-27 |
Аблинкс Нв |
Улучшенные аминокислотные последовательности против il-6r и содержащие их полипептиды для лечения связанных с il-6r заболеваний и нарушений
|
WO2010115995A2
(en)
|
2009-04-10 |
2010-10-14 |
Ablynx Nv |
Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
|
MX2011011670A
(es)
*
|
2009-05-01 |
2011-11-18 |
Abbott Lab |
Inmunoglobulinas de dominio variable dual y usos de las mismas.
|
RU2011151069A
(ru)
|
2009-05-15 |
2013-06-20 |
Чугаи Сейяку Кабусики Кайся |
Анти-axl антитело
|
WO2011011300A2
(en)
|
2009-07-20 |
2011-01-27 |
Centocor Ortho Biotech Inc. |
Differentiation of human embryonic stem cells
|
EP2460538B1
(de)
*
|
2009-07-31 |
2017-09-13 |
Shin Maeda |
Tumormetastasenhemmer
|
WO2011037158A1
(ja)
|
2009-09-24 |
2011-03-31 |
中外製薬株式会社 |
抗体定常領域改変体
|
TW201118166A
(en)
|
2009-09-24 |
2011-06-01 |
Chugai Pharmaceutical Co Ltd |
HLA class I-recognizing antibodies
|
CA2775959A1
(en)
*
|
2009-10-15 |
2011-04-21 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
KR101985153B1
(ko)
|
2009-10-26 |
2019-05-31 |
에프. 호프만-라 로슈 아게 |
글리코실화된 면역글로불린의 제조 방법
|
UY32979A
(es)
*
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
JP5934652B2
(ja)
|
2009-11-24 |
2016-06-15 |
アルダーバイオ ホールディングス エルエルシー |
Il−6に対する抗体およびその使用
|
US9775921B2
(en)
|
2009-11-24 |
2017-10-03 |
Alderbio Holdings Llc |
Subcutaneously administrable composition containing anti-IL-6 antibody
|
MX339669B
(es)
|
2009-12-23 |
2016-06-02 |
Janssen Biotech Inc |
Diferenciacion de celulas madres embrionarias humanas.
|
RU2610176C2
(ru)
|
2009-12-23 |
2017-02-08 |
Янссен Байотек, Инк. |
Дифференцировка человеческих эмбриональных стволовых клеток
|
DK2519542T3
(en)
|
2009-12-28 |
2019-01-14 |
Onco Therapy Science Inc |
ANTI-CDH3 ANTIBODIES AND APPLICATIONS THEREOF.
|
JO3417B1
(ar)
|
2010-01-08 |
2019-10-20 |
Regeneron Pharma |
الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
|
WO2011088215A2
(en)
*
|
2010-01-13 |
2011-07-21 |
Oncomed Pharmaceuticals, Inc. |
Notch1 binding agents and methods of use thereof
|
TWI505838B
(zh)
|
2010-01-20 |
2015-11-01 |
Chugai Pharmaceutical Co Ltd |
Stabilized antibody solution containing
|
MX358451B
(es)
|
2010-03-01 |
2018-08-20 |
Janssen Biotech Inc |
Métodos para purificar células derivadas de células madre pluripotenciales.
|
US10435458B2
(en)
|
2010-03-04 |
2019-10-08 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variants with reduced Fcgammar binding
|
CN102869381A
(zh)
|
2010-03-04 |
2013-01-09 |
大日本住友制药株式会社 |
用于炎性肠病的药物
|
WO2011128096A1
(en)
|
2010-04-16 |
2011-10-20 |
Roche Diagnostics Gmbh |
Polymorphism markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
|
ES2728900T3
(es)
|
2010-05-12 |
2019-10-29 |
Janssen Biotech Inc |
Diferenciación de células madre embrionarias humanas
|
EP3195880B1
(de)
|
2010-05-14 |
2019-11-27 |
Amgen Inc. |
Hoch-konzentrierte anti-sclerostin antikörperformulierungen
|
DK2578231T3
(da)
|
2010-05-28 |
2022-12-12 |
Chugai Pharmaceutical Co Ltd |
Antitumor-t-celle-reaktionsforstærker
|
US20130149302A1
(en)
|
2010-05-28 |
2013-06-13 |
Chugai Seiyaku Kabushiki Kaisha |
Therapeutic agents for pancreatic cancer
|
AU2011259924A1
(en)
|
2010-06-02 |
2013-01-24 |
Sumitomo Dainippon Pharma Co., Ltd. |
Treatment drug for autoimmune diseases and allergic diseases
|
EP2576824A2
(de)
|
2010-06-07 |
2013-04-10 |
Roche Diagnostics GmbH |
Genexpressionsmarker zur vorhersage der reaktion auf eine behandlung mit einem interleukin-6-hemmenden monoklonalen antikörper
|
JO3330B1
(ar)
*
|
2010-06-10 |
2019-03-13 |
Lilly Co Eli |
الأجسام المضادة cgrp
|
AU2011285852B2
(en)
|
2010-08-03 |
2014-12-11 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
US8822663B2
(en)
|
2010-08-06 |
2014-09-02 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
CN103260639A
(zh)
|
2010-08-26 |
2013-08-21 |
Abbvie公司 |
双重可变结构域免疫球蛋白及其用途
|
WO2012030538A2
(en)
|
2010-08-31 |
2012-03-08 |
Janssen Biotech, Inc. |
Differentiation of human embryonic stem cells
|
AU2011308496A1
(en)
|
2010-10-01 |
2013-05-02 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
MX2013004761A
(es)
|
2010-10-29 |
2013-08-27 |
Immunogen Inc |
Nuevas moleculas de union al receptor del factor de crecimiento epidermico (egfr) e inmunoconjugados de estas.
|
WO2012058592A2
(en)
|
2010-10-29 |
2012-05-03 |
Immunogen, Inc. |
Non-antagonistic egfr-binding molecules and immunoconjugates thereof
|
KR101933197B1
(ko)
|
2010-11-08 |
2018-12-27 |
제넨테크, 인크. |
피하 투여용 항―il―6 수용체 항체
|
JP6013915B2
(ja)
|
2010-11-17 |
2016-10-25 |
中外製薬株式会社 |
血液凝固第viii因子の機能を代替する機能を有する多重特異性抗原結合分子
|
EP2643016A2
(de)
|
2010-11-23 |
2013-10-02 |
Alder Biopharmaceuticals, Inc. |
Antikörper gegen il6 zur behandlung von anämie
|
SG10201509790YA
(en)
|
2010-11-30 |
2015-12-30 |
Chugai Pharmaceutical Co Ltd |
Antigen-Binding Molecule Capable Of Binding To Plurality Of Antigen Molecules Repeatedly
|
CN112812184A
(zh)
|
2011-02-25 |
2021-05-18 |
中外制药株式会社 |
FcγRIIb特异性Fc抗体
|
CA2828000A1
(en)
|
2011-03-01 |
2012-09-07 |
Amgen Inc. |
Bispecific binding agents
|
MY170720A
(en)
|
2011-03-25 |
2019-08-27 |
Amgen Inc |
Antibody formulations
|
DE12722942T1
(de)
|
2011-03-31 |
2021-09-30 |
Modernatx, Inc. |
Freisetzung und formulierung von manipulierten nukleinsäuren
|
DK3006464T3
(en)
|
2011-06-10 |
2018-09-17 |
Canada Minister Nat Defence |
ANTIRICIN ANTIBODIES AND APPLICATIONS THEREOF
|
US10400029B2
(en)
|
2011-06-28 |
2019-09-03 |
Inhibrx, Lp |
Serpin fusion polypeptides and methods of use thereof
|
CN103917563A
(zh)
|
2011-06-28 |
2014-07-09 |
英伊布里克斯有限责任公司 |
丝氨酸蛋白酶抑制蛋白融合多肽及其使用方法
|
EP2735315B1
(de)
|
2011-07-19 |
2019-10-02 |
Chugai Seiyaku Kabushiki Kaisha |
Proteinhaltige stabile zubereitung mit argininamid oder valinamid
|
AR087305A1
(es)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
WO2013017656A1
(en)
|
2011-08-02 |
2013-02-07 |
Medizinische Universität Wien |
Antagonists of ribonucleases for treating obesity
|
EP2739652B1
(de)
|
2011-08-04 |
2017-04-05 |
Medizinische Universität Innsbruck |
Cahgt1p-hemmer zur verwendung bei der behandlung von kandidiose
|
SI2739311T1
(en)
|
2011-08-04 |
2018-07-31 |
Amgen Inc. |
Method for the treatment of bone defect defects
|
MX359235B
(es)
|
2011-09-01 |
2018-09-20 |
Chugai Pharmaceutical Co Ltd |
Metodo para preparar una composicion que comprende anticuerpos altamente concentrados por ultrafiltracion.
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
US10138302B2
(en)
|
2011-09-23 |
2018-11-27 |
Ablynx N.V. |
Methods for treating rheumatoid arthritis by administering interleukin-6 receptor antibodies
|
TW201817745A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之FcRn結合域的治療性抗原結合分子
|
US20150050269A1
(en)
|
2011-09-30 |
2015-02-19 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
|
DE102011083811A1
(de)
*
|
2011-09-30 |
2013-04-04 |
Airbus Operations Gmbh |
Sitzvorrichtung für ein Luft- oder Raumfahrzeug
|
WO2013052523A1
(en)
|
2011-10-03 |
2013-04-11 |
modeRNA Therapeutics |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
TWI589299B
(zh)
|
2011-10-11 |
2017-07-01 |
再生元醫藥公司 |
用於治療類風濕性關節炎之組成物及其使用方法
|
WO2013059548A1
(en)
|
2011-10-19 |
2013-04-25 |
Sanofi |
Compositions and methods for treating cancer using jak2 inhibitor
|
SG11201401518TA
(en)
|
2011-10-28 |
2014-05-29 |
Teva Pharmaceuticals Australia Pty Ltd |
Polypeptide constructs and uses thereof
|
JO3370B1
(ar)
|
2011-11-10 |
2019-03-13 |
Regeneron Pharma |
طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
|
WO2013078271A1
(en)
|
2011-11-21 |
2013-05-30 |
Immunogen, Inc. |
Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate
|
US20140295497A1
(en)
|
2011-11-30 |
2014-10-02 |
Taymar E. Hartman |
Vectors and host cells comprising a modified sv40 promoter for protein expression
|
CN104114192A
(zh)
*
|
2011-12-13 |
2014-10-22 |
诺帝克纳诺维科特公司 |
嵌合的治疗性抗-cd37抗体hh1
|
CA2859387A1
(en)
|
2011-12-16 |
2013-06-20 |
Moderna Therapeutics, Inc. |
Modified nucleoside, nucleotide, and nucleic acid compositions
|
AU2012355698B2
(en)
|
2011-12-22 |
2018-11-29 |
Janssen Biotech, Inc. |
Differentiation of human embryonic stem cells into single hormonal insulin positive cells
|
CA2858974A1
(en)
|
2011-12-28 |
2013-07-04 |
Amgen Inc. |
Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
|
EP2797955A2
(de)
|
2011-12-30 |
2014-11-05 |
AbbVie Inc. |
Immunglobuline mit zweifacher variabler domäne gegen il-13 und/oder il-17
|
BR112014022812A2
(pt)
|
2012-03-15 |
2017-07-18 |
Janssen Biotech Inc |
anticorpos anti-cd27 humanos, métodos e usos
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
WO2013151669A1
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
US10501512B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides
|
KR102064025B1
(ko)
|
2012-04-17 |
2020-01-08 |
에프. 호프만-라 로슈 아게 |
수식된 핵산을 사용하는 폴리펩티드의 발현 방법
|
KR101510831B1
(ko)
*
|
2012-05-11 |
2015-04-10 |
가톨릭대학교 산학협력단 |
항 il-6r 및 tnfr2을 포함하는 이중특이적 단백질을 발현하는 미니서클 벡터를 포함하는 줄기세포 치료제
|
KR101510830B1
(ko)
|
2012-05-11 |
2015-04-10 |
가톨릭대학교 산학협력단 |
생리활성 단백질을 발현하는 미니서클을 이용하여 형질전환된 줄기세포를 통한 치료법
|
KR101510302B1
(ko)
*
|
2012-05-11 |
2015-04-10 |
가톨릭대학교 산학협력단 |
Il-6 수용체를 표적으로 하는 항체가 생성되도록 미니서클 벡터를 통해 형질전환된 줄기세포 치료제
|
EP3450542B1
(de)
|
2012-06-08 |
2021-09-01 |
Janssen Biotech, Inc. |
Differenzierung humaner embryonaler stammzellen in endokrine pankreaszellen
|
JP6770312B2
(ja)
|
2012-07-05 |
2020-10-14 |
ユセベ ファルマ ソシエテ アノニム |
骨疾患の治療
|
AU2013316441B2
(en)
|
2012-09-13 |
2018-08-09 |
Chugai Seiyaku Kabushiki Kaisha |
Gene knock-in non-human animal
|
US9487590B2
(en)
|
2012-09-25 |
2016-11-08 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
|
MY171664A
(en)
|
2012-11-01 |
2019-10-22 |
Abbvie Inc |
Anti-dll4/vegf dual variable domain immunoglobulins and uses thereof
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
US9597380B2
(en)
|
2012-11-26 |
2017-03-21 |
Modernatx, Inc. |
Terminally modified RNA
|
ES2837763T3
(es)
|
2012-12-31 |
2021-07-01 |
Janssen Biotech Inc |
Cultivo de células madre embrionarias humanas en la interconexión aire-líquido para la diferenciación en células endocrinas pancreáticas
|
US10370644B2
(en)
|
2012-12-31 |
2019-08-06 |
Janssen Biotech, Inc. |
Method for making human pluripotent suspension cultures and cells derived therefrom
|
SG11201505112SA
(en)
|
2012-12-31 |
2015-07-30 |
Janssen Biotech Inc |
Differentiation of human embryonic stem cells into pancreatic endocrine cells using hb9 regulators
|
KR20150103203A
(ko)
|
2012-12-31 |
2015-09-09 |
얀센 바이오테크 인코포레이티드 |
췌장 내분비 세포 내로의 분화를 위한 인간 만능 세포의 현탁 및 클러스터링
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
EP2970459A2
(de)
|
2013-03-15 |
2016-01-20 |
AbbVie Inc. |
Gegen il-1beta und il-17 gerichtete duale spezifische bindungsproteine
|
US11117975B2
(en)
|
2013-04-29 |
2021-09-14 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
|
PL3677591T3
(pl)
|
2013-04-29 |
2023-06-26 |
Teva Pharmaceuticals Australia Pty Ltd |
Przeciwciała anty-cd38 i fuzje z interferonem alfa-2b o osłabionej aktywności
|
US10782290B2
(en)
|
2013-06-11 |
2020-09-22 |
National Center Of Neurology And Psychiatry |
Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
|
RU2674996C2
(ru)
|
2013-07-04 |
2018-12-14 |
Ф. Хоффманн-Ля Рош Аг |
Иммуноферментный анализ с подавлением интерференции для определения антител к лекарствам в образцах сыворотки
|
US11124576B2
(en)
|
2013-09-27 |
2021-09-21 |
Chungai Seiyaku Kabushiki Kaisha |
Method for producing polypeptide heteromultimer
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
EP3052521A1
(de)
|
2013-10-03 |
2016-08-10 |
Moderna Therapeutics, Inc. |
Polynukleotide zur codierung von low-density-lipoprotein-rezeptor
|
DE202014010499U1
(de)
|
2013-12-17 |
2015-10-20 |
Kymab Limited |
Targeting von humaner PCSK9 zur Cholesterinbehandlung
|
US9017678B1
(en)
|
2014-07-15 |
2015-04-28 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
MX2016008472A
(es)
|
2013-12-26 |
2016-10-28 |
Mitsubishi Tanabe Pharma Corp |
Anticuero monoclonal neutralizador de anti-il-33-humana.
|
SG11201605256YA
(en)
|
2013-12-27 |
2016-08-30 |
Chugai Pharmaceutical Co Ltd |
Method for purifying antibody having low isoelectric point
|
EP2898896A1
(de)
|
2014-01-22 |
2015-07-29 |
Université Pierre et Marie Curie (Paris 6) |
Mittel zur Verwendung bei der Behandlung von Netzhautentzündung
|
WO2015116852A1
(en)
|
2014-01-29 |
2015-08-06 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating rheumatoid arthritis by administering an il-6r antibody
|
RU2020124944A
(ru)
|
2014-03-21 |
2020-08-27 |
Эббви Инк. |
Антитела против egfr и конъюгаты антитело-лекарственное средство
|
UA119352C2
(uk)
|
2014-05-01 |
2019-06-10 |
Тева Фармасьютикалз Острейліа Пті Лтд |
Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
|
DK3143127T3
(da)
|
2014-05-16 |
2021-09-13 |
Janssen Biotech Inc |
Anvendelse af små molekyler til at forstærke mafa-ekspression i endokrine pankreasceller
|
EP4056993A1
(de)
|
2014-08-20 |
2022-09-14 |
Chugai Seiyaku Kabushiki Kaisha |
Verfahren zur messung der viskosität einer proteinlösung
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
CA2963712A1
(en)
|
2014-10-21 |
2016-04-28 |
Ablynx Nv |
Treatment of il-6r related diseases
|
KR102639037B1
(ko)
|
2014-10-29 |
2024-02-20 |
테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 |
인터페론 α2b 변이체
|
WO2016094881A2
(en)
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
MA41142A
(fr)
|
2014-12-12 |
2017-10-17 |
Amgen Inc |
Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
|
WO2016100233A1
(en)
|
2014-12-15 |
2016-06-23 |
The Regents Of The University Of California |
Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
|
BR112017006736A2
(pt)
|
2014-12-19 |
2017-12-19 |
Chugai Pharmaceutical Co Ltd |
anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes, e métodos de utilização
|
CN107207607B
(zh)
|
2014-12-19 |
2021-05-04 |
中外制药株式会社 |
抗-c5抗体及使用方法
|
SG11201706014PA
(en)
|
2015-02-05 |
2017-08-30 |
Chugai Pharmaceutical Co Ltd |
Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
|
TW202339800A
(zh)
|
2015-02-27 |
2023-10-16 |
日商中外製藥股份有限公司 |
Il-6受體抗體用於製備醫藥組成物的用途
|
AR104050A1
(es)
|
2015-03-26 |
2017-06-21 |
Chugai Pharmaceutical Co Ltd |
Proceso de producción con iones de cobre controlados
|
JP7082484B2
(ja)
|
2015-04-01 |
2022-06-08 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
ES2888801T3
(es)
|
2015-05-19 |
2022-01-07 |
Nat Center Neurology & Psychiatry |
Método para determinar la aplicación de una terapia nueva en pacientes con esclerosis múltiple (EM)
|
EP3305325A4
(de)
|
2015-06-04 |
2019-01-16 |
National Center of Neurology and Psychiatry |
Wirkstoff zur therapie von geisteskrankheiten mit il-6-hemmer als wirkstoff
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
US10772956B2
(en)
|
2015-08-18 |
2020-09-15 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab
|
EP3371224A1
(de)
|
2015-11-03 |
2018-09-12 |
Sanofi Biotechnology |
Zusammensetzungen mit il6r-antikörpern zur behandlung von uveitis und makulaödem und verfahren zur verwendung davon
|
JP7141336B2
(ja)
|
2015-12-25 |
2022-09-22 |
中外製薬株式会社 |
抗ミオスタチン抗体および使用方法
|
SG11201803989WA
(en)
|
2015-12-28 |
2018-06-28 |
Chugai Pharmaceutical Co Ltd |
Method for promoting efficiency of purification of fc region-containing polypeptide
|
WO2017147169A1
(en)
|
2016-02-22 |
2017-08-31 |
Ohio State Innovation Foundation |
Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin a analogues or metabolites, and estradiol metabolites
|
GB201604124D0
(en)
|
2016-03-10 |
2016-04-27 |
Ucb Biopharma Sprl |
Pharmaceutical formulation
|
TW202214700A
(zh)
|
2016-03-14 |
2022-04-16 |
日商中外製藥股份有限公司 |
用於癌之治療的細胞傷害誘導治療劑
|
MA45479A
(fr)
|
2016-04-14 |
2019-02-20 |
Janssen Biotech Inc |
Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen
|
CA3026050A1
(en)
|
2016-08-05 |
2018-02-08 |
Chugai Seiyaku Kabushiki Kaisha |
Composition for prophylaxis or treatment of il-8 related diseases
|
AU2017319702A1
(en)
|
2016-09-02 |
2019-04-11 |
The Regents Of The University Of California |
Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
KR102546471B1
(ko)
|
2016-09-27 |
2023-06-21 |
프레제니우스 카비 도이치란트 게엠베하 |
액상의 약학 조성물
|
KR102051177B1
(ko)
*
|
2016-10-19 |
2019-12-17 |
주식회사 엘지화학 |
전압 분배를 이용한 스위치 진단 장치 및 방법
|
CA3040342A1
(en)
|
2016-10-31 |
2018-05-03 |
Fresenius Kabi Deutschland Gmbh |
Liquid pharmaceutical composition
|
WO2018156180A1
(en)
|
2017-02-24 |
2018-08-30 |
Kindred Biosciences, Inc. |
Anti-il31 antibodies for veterinary use
|
WO2018170405A1
(en)
|
2017-03-17 |
2018-09-20 |
Ohio State Innovation Foundation |
Nanoparticles for delivery of chemopreventive agents
|
JP7185884B2
(ja)
|
2017-05-02 |
2022-12-08 |
国立研究開発法人国立精神・神経医療研究センター |
Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法
|
CN107098969B
(zh)
*
|
2017-06-28 |
2018-10-12 |
武汉波睿达生物科技有限公司 |
一种治疗hiv感染的嵌合抗原受体的重组基因构建及其应用
|
BR112020003458A2
(pt)
|
2017-08-31 |
2020-08-25 |
Mitsubishi Tanabe Pharma Corporation |
agente terapêutico contendo antagonistas il-33 para endometriose
|
MX2020002750A
(es)
|
2017-09-13 |
2020-07-20 |
Jiangsu Hengrui Medicine Co |
Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
|
US11692037B2
(en)
|
2017-10-20 |
2023-07-04 |
Hyogo College Of Medicine |
Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
|
TWI822728B
(zh)
|
2018-01-31 |
2023-11-21 |
加藤元一 |
含有il-6抑制劑的哮喘治療劑
|
CN112119090B
(zh)
|
2018-03-15 |
2023-01-13 |
中外制药株式会社 |
对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
|
WO2019191534A1
(en)
|
2018-03-30 |
2019-10-03 |
Amgen Inc. |
C-terminal antibody variants
|
KR20210010996A
(ko)
|
2018-05-21 |
2021-01-29 |
추가이 세이야쿠 가부시키가이샤 |
유리 용기에 봉입된 동결건조 제제
|
CN112243423B
(zh)
|
2018-05-28 |
2022-11-04 |
中外制药株式会社 |
填充喷嘴
|
AU2019329958A1
(en)
|
2018-08-29 |
2021-03-18 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for treating subjects having rheumatoid arthritis
|
BR112021014377A2
(pt)
|
2019-01-31 |
2021-12-28 |
Regeneron Pharma |
Composições e métodos para o tratamento de artrite idiopática juvenil
|
BR112021017702A2
(pt)
|
2019-03-29 |
2021-11-16 |
Chugai Pharmaceutical Co Ltd |
Inibidor contendo anticorpo anti-receptor de il-6 para inibição de deterioração da função bhe
|
US20220177978A1
(en)
|
2019-04-02 |
2022-06-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of predicting and preventing cancer in patients having premalignant lesions
|
WO2020209318A1
(ja)
|
2019-04-10 |
2020-10-15 |
中外製薬株式会社 |
Fc領域改変抗体の精製方法
|
TW202110477A
(zh)
|
2019-04-17 |
2021-03-16 |
國立大學法人廣島大學 |
以組合投予il-6 抑制劑與ccr2 抑制劑為特徵之泌尿器官癌的治療劑
|
EP3986481A2
(de)
|
2019-06-20 |
2022-04-27 |
Takeda Pharmaceutical Company Limited |
Verfahren zur behandlung mit einer auf viren basierenden gentherapie
|
CN110483640B
(zh)
*
|
2019-07-16 |
2020-05-01 |
北京汇智和源生物技术有限公司 |
白介素-6r的人源化单克隆抗体、其编码基因及应用
|
WO2021178420A1
(en)
|
2020-03-03 |
2021-09-10 |
Twentyeight-Seven, Inc. |
Compounds targeting rna-binding proteins or rna-modifying proteins
|
US20230174656A1
(en)
|
2020-03-23 |
2023-06-08 |
Genentech, Inc. |
Tocilizumab and remdesivir combination therapy for covid-19 pneumonia
|
JP2023518814A
(ja)
|
2020-03-23 |
2023-05-08 |
ジェネンテック, インコーポレイテッド |
Covid-19肺炎における、il-6アンタゴニストに対する応答を予測するためのバイオマーカー
|
JP2023518815A
(ja)
|
2020-03-23 |
2023-05-08 |
ジェネンテック, インコーポレイテッド |
Il6アンタゴニストによるcovid-19肺炎を含む肺炎の治療方法
|
WO2021211006A1
(en)
|
2020-04-13 |
2021-10-21 |
Federal State Budgetary Institution Center Of Biomedical Technologies Of Federal Medical And Biological Agency |
Inhaled hexapeptide for treating interleukin-6 related respiratory diseases
|
WO2021228917A1
(en)
|
2020-05-15 |
2021-11-18 |
F. Hoffmann-La Roche Ag |
Prevention of visible particle formation in parenteral protein solutions
|
WO2022005321A1
(en)
|
2020-06-29 |
2022-01-06 |
Federal State Budgetary Institution Scientific center of biomedical technologies of Federal Medical and Biological Agency |
Inhaled tocilizumab for treating interleukin-6 related respiratory diseases
|
KR20220028972A
(ko)
|
2020-08-31 |
2022-03-08 |
(주)셀트리온 |
안정한 약제학적 제제
|
JP2023541921A
(ja)
|
2020-09-17 |
2023-10-04 |
ジェネンテック, インコーポレイテッド |
Covid-19肺炎を有する入院患者におけるトシリズマブの有効性及び安全性を評価するためのランダム化二重盲検プラセボ対照多施設試験(empacta)の結果
|
UY39610A
(es)
|
2021-01-20 |
2022-08-31 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
WO2022165419A1
(en)
|
2021-02-01 |
2022-08-04 |
Kyverna Therapeutics, Inc. |
Methods for increasing t-cell function
|
AU2022232856A1
(en)
|
2021-03-12 |
2023-10-26 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical composition for treatment or prevention of myasthenia gravis
|
EP4352101A1
(de)
|
2021-06-11 |
2024-04-17 |
Genentech, Inc. |
Verfahren zur behandlung von chronisch obstruktiver lungenerkrankung mit einem st2-antagonisten
|
TW202323810A
(zh)
|
2021-10-08 |
2023-06-16 |
日商中外製藥股份有限公司 |
預填充式注射器製劑的調製方法
|
WO2024107752A2
(en)
|
2022-11-15 |
2024-05-23 |
Onestone Therapeutics Llc |
Compositions and methods for immunomodulatory bifunctional fusion molecules
|